MRI Interventions’ ClearPoint® Neuro Navigation System to be Featured at ASSFN Biennial Meeting
Use of ClearPoint to be Reviewed in Key Symposium
IRVINE, Calif., June 15, 2016 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a commercial stage medical device company focused on creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain, today announced that its ClearPoint Neuro Navigation System will be featured in a Symposium, titled “Real-Time IMRI Guidance and Laser Ablation Move into the Mainstream,” on Sunday, June 19, 2016 at the Biennial Meeting of the American Society for Stereotactic and Functional Neurosurgery (ASSFN) taking place on June 18 through 21, 2016 in Chicago, Illinois.
The symposium will feature lectures by Dr. Paul Larson, from the University of California, San Francisco Medical Center, and Dr. Veronica Chiang, from Yale-New Haven University. Each neurosurgeon will review their clinical experience with the ClearPoint Neuro Navigation System in deep brain stimulation, drug delivery and/or laser ablation.
“Nearly 1,200 patients have been treated with the sub-millimeter accuracy and real-time, MRI-based visualization enabled by our ClearPoint Neuro Navigation System,” commented Wendelin Maners, MRI Interventions, Vice President of Marketing. “We are proud to work with innovative neurosurgeons and medical centers to offer minimally invasive surgical options for their patients.”
The ASSFN covers the latest clinical and research advances in epilepsy, movement disorders, pain, neural engineering, and emerging technologies in functional neurosurgery. ASSFN attendees are invited to visit MRI Interventions’ booth (#102) to learn about the ClearPoint System platform.
The ClearPoint Neuro Navigation System allows surgeons to plan, target, and adjust trajectories of electrodes, catheters and needles under real time MRI-guided visualization without attaching a large, metal stereotactic headframe to the patient. Real time MRI imaging provides the surgeon with current views of the patient’s brain anatomy at the time of surgical planning, device alignment, and navigation of the device to target, resulting in improved accuracy and reduced risk of brain shift associated with standard imaging techniques. In addition, the entire procedure takes place in an MRI suite and eliminates the need to move the patient to and from an operating room and an MRI scanner.
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of the Company’s products; its ability to successfully expand, and achieve full productivity from, its sales, clinical support and marketing capabilities; its ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of its cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact its commercialization efforts. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission.
Contact: Wendelin Maners, VP, Marketing MRI Interventions, Inc. 949-900-6833